| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
ID: ALA4753197
Max Phase: Preclinical
Molecular Formula: C18H23N3O3S2
Molecular Weight: 393.53
Molecule Type: Unknown
Associated Items:
Representations
Canonical SMILES: CC(C)c1cccc(C(C)C)c1NC(=O)NS(=O)(=O)/C=C/c1nccs1
Standard InChI: InChI=1S/C18H23N3O3S2/c1-12(2)14-6-5-7-15(13(3)4)17(14)20-18(22)21-26(23,24)11-8-16-19-9-10-25-16/h5-13H,1-4H3,(H2,20,21,22)/b11-8+
Standard InChI Key: MILCEDFUBXAZNY-DHZHZOJOSA-N
Associated Targets(Human)
NACHT, LRR and PYD domains-containing protein 3 908 Activities
Molecule Features
| Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
| Molecule Type: Unknown | Topical: No | First In Class: No | Black Box: No |
| Chirality: No | Availability: No | Prodrug: No |
Drug Indications
| MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
|---|
Mechanisms of Action
| Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
|---|
Properties
| Molecular Weight: 393.53 | Molecular Weight (Monoisotopic): 393.1181 | AlogP: 4.51 | #Rotatable Bonds: 6 |
| Polar Surface Area: 88.16 | Molecular Species: ACID | HBA: 5 | HBD: 2 |
| #RO5 Violations: 0 | HBA (Lipinski): 6 | HBD (Lipinski): 2 | #RO5 Violations (Lipinski): 0 |
| CX Acidic pKa: 3.67 | CX Basic pKa: 2.48 | CX LogP: 3.88 | CX LogD: 3.13 |
| Aromatic Rings: 2 | Heavy Atoms: 26 | QED Weighted: 0.76 | Np Likeness Score: -1.36 |
References
| 1. Agarwal S,Pethani JP,Shah HA,Vyas V,Sasane S,Bhavsar H,Bandyopadhyay D,Giri P,Viswanathan K,Jain MR,Sharma R. (2020) Identification of a novel orally bioavailable NLRP3 inflammasome inhibitor., 30 (21.0): [PMID:32980515] [10.1016/j.bmcl.2020.127571] |
Source
Source(1):